PRESS RELEASE published on 07/15/2024 at 09:30, 2 years 3 months ago Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca Andera Partners' portfolio company Amolyt Pharma has been acquired by AstraZeneca for $1.05 billion, enhancing AstraZeneca's Rare Disease late-stage pipeline and bone metabolism franchise Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Andera Partners
BRIEF published on 07/09/2024 at 08:15, 2 years 3 months ago Andera Partners codirige la série A de 63 millions d'euros pour la biotechnologie SciRhom Produits Biopharmaceutiques Maladies Auto-immunes Financement De Série A Partenaires Andera SciRhom
BRIEF published on 07/09/2024 at 08:15, 2 years 3 months ago Andera Partners Co-Leads €63 Million Series A for Biotech SciRhom Series A Financing Biopharmaceuticals Andera Partners Autoimmune Disorders SciRhom
PRESS RELEASE published on 07/09/2024 at 08:10, 2 years 3 months ago Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom to advance novel iRhom2 antibody therapy towards clinical proof-of-concept Andera Partners SciRhom Autoimmune Biotech Series A Round IRhom2 Antibody
BRIEF published on 03/14/2024 at 11:15, 2 years 7 months ago Tubulis, la société de portefeuille d'Andera Partners, obtient un financement de série B2 de 128 millions d'euros Essais Cliniques Tubulis Partenaires Andera Financement De Série B2 Développement ADC
BRIEF published on 03/14/2024 at 11:15, 2 years 7 months ago Andera Partners’ Portfolio Company Tubulis Secures €128 Million in Series B2 Financing Clinical Trials Andera Partners Tubulis Series B2 Financing ADC Development
PRESS RELEASE published on 03/14/2024 at 11:10, 2 years 7 months ago Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 to accelerate the development of its ADC Pipeline Andera Partners’ portfolio company Tubulis closes upsized €128 Million Series B2 financing to accelerate ADC pipeline development Andera Partners Tubulis €128 Million Series B2 ADC Pipeline Biotech Financing
BRIEF published on 03/14/2024 at 09:05, 2 years 7 months ago AstraZeneca acquiert Amolyt Pharma pour un montant pouvant atteindre 1,05 milliard de dollars Acquisition Biopharmaceutique AstraZeneca Amolyt Pharma Maladies Rares
BRIEF published on 03/14/2024 at 09:05, 2 years 7 months ago AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion Acquisition Biopharmaceutical AstraZeneca Amolyt Pharma Rare Diseases
PRESS RELEASE published on 03/14/2024 at 09:00, 2 years 7 months ago Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca Amolyt Pharma, a clinical-stage biopharmaceutical company specializing in therapeutic peptides, is being acquired by AstraZeneca for $1.05 billion. The transaction is expected to close in Q3 2024 Acquisition AstraZeneca Amolyt Pharma Therapeutic Peptides Rare Endocrine Diseases
Published on 11/05/2026 at 15:20, 32 minutes ago MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 1 hour 21 minutes ago First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 1 hour 27 minutes ago Polaris Renewable Energy Announces Q3 2026 Results
Published on 11/05/2026 at 14:20, 1 hour 32 minutes ago Polaris Renewable Energy Declares Quarterly Dividend
Published on 11/05/2026 at 14:15, 1 hour 37 minutes ago Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook
Published on 11/05/2026 at 15:34, 17 minutes ago Finexity AG: NuWays and GBC confirm price targets following Capital Markets Day and 9-month figures, taking the share split into account
Published on 11/05/2026 at 15:10, 42 minutes ago Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer
Published on 11/05/2026 at 14:58, 54 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/05/2026 at 15:01, 51 minutes ago Chiffre d'Affaires du 1er semestre de l'exercice 2026/2027
Published on 11/05/2026 at 10:16, 5 hours 36 minutes ago Accélération confirmée au troisième trimestre 2026 Tous les métiers en croissance, chiffre d’affaires en progression de +6,5 %
Published on 11/05/2026 at 10:16, 5 hours 36 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
